1.3(top 50%)
impact factor
699(top 20%)
papers
4.3K(top 20%)
citations
30(top 20%)
h-index
1.4(top 50%)
extended IF
862
all documents
4.9K
doc citations
40(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk EvaluationStatistics in Biopharmaceutical Research201693
2Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface ModelStatistics in Biopharmaceutical Research201886
3Multiple Testing in Group Sequential Trials Using Graphical ApproachesStatistics in Biopharmaceutical Research201381
4Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicStatistics in Biopharmaceutical Research202065
5Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative AnalysisStatistics in Biopharmaceutical Research202064
6A Simulation Study to Compare New Adaptive Dose–Ranging DesignsStatistics in Biopharmaceutical Research201058
7Statistical Considerations on Subgroup Analysis in Clinical TrialsStatistics in Biopharmaceutical Research201556
8Meta-Analysis of Clinical Dose–Response in a Large Drug Development PortfolioStatistics in Biopharmaceutical Research201455
9Responder Analyses—A PhRMA Position PaperStatistics in Biopharmaceutical Research201146
10Estimands and Their Role in Clinical TrialsStatistics in Biopharmaceutical Research201745
11Personalized Medicine: Four Perspectives of Tailored MedicineStatistics in Biopharmaceutical Research201544
12Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One StudyStatistics in Biopharmaceutical Research201644
13Chain Procedures: A Class of Flexible Closed Testing Procedures With Clinical Trial ApplicationsStatistics in Biopharmaceutical Research201142
14The Role of p-Values in Judging the Strength of Evidence and Realistic Replication ExpectationsStatistics in Biopharmaceutical Research202142
15The ICH Q8 Definition of Design Space: A Comparison of the Overlapping Means and the Bayesian Predictive ApproachesStatistics in Biopharmaceutical Research201041
16Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase IIIStatistics in Biopharmaceutical Research201041
17Causal Inference and Estimands in Clinical TrialsStatistics in Biopharmaceutical Research202041
18Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging StudiesStatistics in Biopharmaceutical Research201040
19Machine learning for clinical trials in the era of COVID-19Statistics in Biopharmaceutical Research202040
20Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19Statistics in Biopharmaceutical Research202040
21Missing Data: Turning Guidance Into ActionStatistics in Biopharmaceutical Research201339
22On the Use of Co-Data in Clinical TrialsStatistics in Biopharmaceutical Research201639
23The Win Ratio: On Interpretation and Handling of TiesStatistics in Biopharmaceutical Research202039
24Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine DevelopmentStatistics in Biopharmaceutical Research200937
25Confidence Intervals of Interaction Index for Assessing Multiple Drug InteractionStatistics in Biopharmaceutical Research200936
26Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug DevelopmentStatistics in Biopharmaceutical Research200935
27Design and Analysis Considerations in Clinical Trials With a Sensitive SubpopulationStatistics in Biopharmaceutical Research201034
28Comparison of Test Statistics for the Sequential Parallel DesignStatistics in Biopharmaceutical Research201034
29Strictly Standardized Mean Difference, Standardized Mean Difference and Classicalt-test for the Comparison of Two GroupsStatistics in Biopharmaceutical Research201034
30Dose Expansion Cohorts in Phase I TrialsStatistics in Biopharmaceutical Research201633
31A Note on Good Practice of Objective Propensity Score Design for Premarket Nonrandomized Medical Device Studies with an ExampleStatistics in Biopharmaceutical Research201632
32The Overlooked Importance of Constants Added in Log Transformation of Independent Variables with Zero Values: A Proposed Approach for Determining an Optimal ConstantStatistics in Biopharmaceutical Research201832
33The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and AnalysisStatistics in Biopharmaceutical Research202332
34Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial ProportionsStatistics in Biopharmaceutical Research201031
35Bridging Solutions in Dose-Finding ProblemsStatistics in Biopharmaceutical Research201431
36Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?Statistics in Biopharmaceutical Research202031
37A Conditional Power Approach to the Evaluation of Predictive PowerStatistics in Biopharmaceutical Research200930
38A Theoretical Framework for Estimation of AUCs in Complete and Incomplete Sampling DesignsStatistics in Biopharmaceutical Research200930
39Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working GroupStatistics in Biopharmaceutical Research202330
40A Bayesian Design Space Approach to Robustness and System Suitability for Pharmaceutical Assays and Other ProcessesStatistics in Biopharmaceutical Research200928
41Sample Size Re-estimation Designs In Confirmatory Clinical Trials—Current State, Statistical Considerations, and Practical GuidanceStatistics in Biopharmaceutical Research201527
42Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary OutcomesStatistics in Biopharmaceutical Research201527
43Borrowing From Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical GuidelinesStatistics in Biopharmaceutical Research201927
44Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset EffectStatistics in Biopharmaceutical Research200926
45Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical TrialsStatistics in Biopharmaceutical Research202026
46Statistical Approaches to Analyzing HIV-1 Neutralizing Antibody Assay DataStatistics in Biopharmaceutical Research201225
47A Generalized Continual Reassessment Method for Two-Agent Phase I TrialsStatistics in Biopharmaceutical Research201324
48Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand FrameworkStatistics in Biopharmaceutical Research202024
49Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape AssessmentStatistics in Biopharmaceutical Research202324
50Global Sensitivity Analysis for Repeated Measures Studies With Informative Dropout: A Fully Parametric ApproachStatistics in Biopharmaceutical Research201423